Mark Basik
Professor
MDCM
My laboratory has expertise in the genomics (DNA microarray technology) of breast and colon cancer. Our major effort is in the identification of novel therapeutic targets in breast and colon cancer using combined array comparative genomic hybridization and gene expression profiling of breast and colon cancer cell lines as well as frozen tumors. Functional validation using RNA interference-mediated gene knockdown as well as clinical validation using tissue microarrays will allow selection of candidate target genes. A specific area of interest is identification of targets of anticancer drug resistance (e.g. herceptin resistance in breast cancer). Another aspect of our work is the discovery of novel diagnostic biomarkers in the above cancers using microarray technology. Serum biomarkers of metastatic disease are being studied in particular.聽
Breast cancer
Dr. Mark Basik was born in Montreal, graduated in medicine from 缅北强奸, completed a general Surgery Residency at the Universit茅 de Montreal, followed by a fellowship in Surgical Oncology at Roswell Park Cancer Institute. He was a visiting investigator at the National Institutes of Health in Bethesda. He returned to Montreal in 2003, where he is now practicing breast cancer surgery at the Jewish General Hospital in Montreal, QC, and he is the Herbert Black professor of Surgical Oncology at 缅北强奸. He heads the Cancer Genomics and Translational Research Laboratory at the Lady Davis Institute for Medical Research. His research interests include understanding the causes of resistance to therapy in breast cancer as well as developing new diagnostic blood tests involving circulating tumor DNA for breast cancer. He co-leads the Molecular Tumor Board at the Jewish General Hospital since 2018.
1.Aguilar-Mahecha A, Alirezaie N, Lafleur J, Bareke E, Przybytkowski E, Lan C, Cavallone L, Salem M, Pelmus M, Aleynikova O, Greenwood C, Lovato A, Ferrario C, Boileau JF, Mihalcioiu C, Roy JA, Marcus E, Discepola F, Majewski J, Basik M. The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers. Genes (Basel). 2023 Dec 23;15(1):27. doi: 10.3390/genes15010027.PMID: 38254917
2.Aguilar-Mahecha A, Lafleur J, Brousse S, Savichtcheva O, Holden KA, Faulkner N, McLennan G, Jensen TJ, Basik M. Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients. Cancers (Basel). 2021 Mar 16;13(6):1331.
3.Cavallone L, Aguilar-Mahecha A, Lafleur J, Brousse S, Aldamry M, Roseshter T, Lan C, Alirezaie N, Bareke E, Majewski J, Ferrario C, Hassan S, Discepola F, Seguin C, Mihalcioiu C, Marcus EA, Robidoux A, Roy JA, Pelmus M, Basik M. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci Rep. 2020 Sep 7;10(1):14704.
4. Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, L茅gar茅 S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. Mol Cancer Res. 2019 Dec;17(12):2492-2507.
